Experienced clinical development executive to succeed current CEO
“Surface has evolved significantly over the past year into a development stage company with multiple promising immuno-oncology programs in clinical development,” Rob said. “Together with our outstanding leadership team and all of Surface’s dedicated employees, I look forward to building on that success and leading the company at this important transition point as we continue to advance and expand our pipeline of novel therapies for patients with cancer.”
In addition to the CEO transition,
“We are delighted that Rob will be the next CEO of Surface Oncology,” Jeff said. “Rob has been a key contributor to Surface’s overall success. His leadership within the organization stretches well beyond clinical development, and his breadth of expertise will be a key driver of our success going forward. With four Surface programs expected to be in clinical development by the end of 2021, including our two wholly owned programs SRF617 and SRF388, Rob is the ideal person to lead the company through its next phase of growth. I also want to thank Dan for his support and guidance over the years. His contributions to Surface’s success have been significant.”
Prior to joining Surface, Rob served as head of oncology at bluebird bio, building a multifaceted oncology program. Before bluebird bio, he worked at
Cautionary Note Regarding Forward-Looking Statements:
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would,” or similar expressions, and the negative of those terms. These forward-looking statements are based on Surface Oncology’s management’s current beliefs and assumptions about future events and on information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Surface Oncology’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to Surface Oncology’s ability to successfully develop SRF388, SRF617, SRF114 and its other product candidates through current and future milestones or regulatory filings on the anticipated timeline, if at all, the therapeutic potential of Surface Oncology’s product candidates, the risk that results from preclinical studies or early clinical trials may not be representative of larger clinical trials, the risk that Surface Oncology’s product candidates, including SRF388, SRF617 and SRF114, will not be successfully developed or commercialized, the risks related to Surface Oncology’s dependence on third-parties in connection with its manufacturing, clinical trials and preclinical studies, and the potential impact of COVID-19 on our clinical and preclinical development timelines and results of operations. Additional risks and uncertainties that could affect Surface Oncology’s future results are included in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ending
Additional information on potential risks will be made available in other filings that
Source: Surface Oncology, Inc.